Structural determinants for the binding of morphinan agonists to the μ-opioid receptor

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Cong, Xiaojing ^a,b   Campomanes, Pablo ^a,b   Kless, Achim ^c   Schapitz, Inga ^c   Wagener, Markus ^c   Koch, Thomas ^c   Carloni, Paolo ^a,b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA FUNALTREXAMINE; HYDROMORPHONE; MORPHINAN AGONIST; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CYCLIC AMP; PROTEIN BINDING; RETINA S ANTIGEN;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; COVALENT BOND; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENERGY; HYDRATION; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR DYNAMICS; METABOLISM; THEORETICAL MODEL; THERMODYNAMICS;

ARRESTINS; CYCLIC AMP; HYDROMORPHONE; MODELS, THEORETICAL; MOLECULAR DYNAMICS SIMULATION; MORPHINE; PROTEIN BINDING; RECEPTORS, OPIOID, MU; THERMODYNAMICS;

EID: 84942915560     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135998     Document Type: Article

References (58)

1. Kuehn BM. Prescription drug abuse rises globally. Jama-Journal of the American Medical Association. 2007; 297(12):1306-. doi: 10.1001/jama.297.12.1306 PMID: WOS:000245212600005.
2. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. British Journal of Pharmacology. 2008; 154(2):384-96. doi: 10.1038/bjp.2008.100 PMID: WOS:000255755900011.
3. Ross S, Peselow E. The Neurobiology of Addictive Disorders. Clinical Neuropharmacology. 2009; 32 (5):269-76. doi: 10.1097/WNF.0b013e3181a9163c PMID: WOS:000270662300007.
4. Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Current Opinion in Pharmacology. 2005; 5(1):60-8. doi: 10.1016/j.coph.2004.08.012 PMID: WOS:000226957400010.
5. Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, et al. The GPCR Network: a largescale collaboration to determine human GPCR structure and function. Nature Reviews Drug Discovery. 2013; 12(1):25-34. doi: 10.1038/nrd3859 PMID: WOS:000312987000013.
6. Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977; 267(5611):495-9. Epub 1977/06/09. PMID: 195217.
7. Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci U S A. 1993; 90(12):5391-3. Epub 1993/06/15. PMID: 8390660; PubMed Central PMCID: PMC46725.
8. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett. 1994; 341 (1):33-8. Epub 1994/03/14. PMID: 8137918.
9. Dreborg S, Sundstrom G, Larsson TA, Larhammar D. Evolution of vertebrate opioid receptors. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(40):15487-92. doi: 10.1073/pnas.0805590105 PMID: WOS:000260360500050.
10. Spetea M, Asim MF, Wolber G, Schmidhammer H. The mu Opioid Receptor and Ligands Acting at the mu Opioid Receptor, as Therapeutics and Potential Therapeutics. Current Pharmaceutical Design. 2013; 19(42):7415-34. PMID: WOS:000329431900010.
11. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. Loss of morphineinduced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996; 383(6603):819-23. doi: 10.1038/383819a0 PMID: WOS:A1996VQ14400062.
12. Law PY, Reggio PH, Loh HH. Opioid receptors: toward separation of analgesic from undesirable effects. Trends in biochemical sciences. 2013; 38(6):275-82. Epub 2013/04/20. doi: 10.1016/j.tibs. 2013.03.003 PMID: 23598157; PubMed Central PMCID: PMC3665630.
13. Zhou L, Bohn LM. Functional selectivity of GPCR signaling in animals. Current Opinion in Cell Biology. 2014; 27:102-8. doi: 10.1016/j.ceb.2013.11.010 PMID: WOS:000335106100015.
14. Rominger DH, Cowan CL, Gowen-MacDonald W, Violin JD. Biased ligands: pathway validation for novel GPCR therapeutics. Current Opinion in Pharmacology. 2014; 16:108-15. doi: 10.1016/j.coph. 2014.04.002 PMID: WOS:000338094300015.
15. Kenakin T. Functional Selectivity and Biased Receptor Signaling. Journal of Pharmacology and Experimental Therapeutics. 2011; 336(2):296-302. doi: 10.1124/jpet.110.173948 PMID: WOS:000286309800001.
16. Lamberts JT, Traynor JR. Opioid Receptor Interacting Proteins and the Control of Opioid Signaling. Current Pharmaceutical Design. 2013; 19(42):7333-47. PMID: WOS:000329431900002.
17. DeWire SM, Yamashita DS, Rominger DH, Liu GD, Cowan CL, Graczyk TM, et al. A G Protein-Biased Ligand at the mu-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphines. Journal of Pharmacology and Experimental Therapeutics. 2013; 344(3):708-17. doi: 10.1124/Jpet.112.201616 PMID: ISI:000315192500017.
18. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. Crystal structure of the mu-opioid receptor bound to a morphinan antagonist. Nature. 2012; 485(7398):321-6. Epub 2012/03/23. doi: 10.1038/nature10954 PMID: 22437502; PubMed Central PMCID: PMC3523197.
19. Rasmussen SGF, DeVree BT, Zou YZ, Kruse AC, Chung KY, Kobilka TS, et al. Crystal structure of the beta(2) adrenergic receptor-Gs protein complex. Nature. 2011; 477(7366):549-U311. doi: 10.1038/ Nature10361 PMID: ISI:000295320900031.
20. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, et al. Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics. 2006;Chapter 5:Unit 5 6. Epub 2008/04/23. doi: 10.1002/0471250953.bi0506s15 PMID: 18428767.
21. Weichenberger CX, Sippl MJ. NQ-Flipper: recognition and correction of erroneous asparagine and glutamine side-chain rotamers in protein structures. Nucleic Acids Research. 2007; 35:W403-W6. doi: 10. 1093/nar/gkm263 PMID: WOS:000255311500075.
22. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pK(a)s and adding missing hydrogens to macromolecules. Nucleic Acids Research. 2005; 33:W368-W71. doi: 10. 1093/nar/gki464 PMID: WOS:000230271400074.
23. Molecular Operating Environment (MOE) 2012.10. 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7: Chemical Computing Group Inc.; 2013.
24. Labute P. Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins. 2009; 75(1):187-205. doi: 10.1002/Prot.22234 PMID: ISI:000263546600016.
25. Labute P. The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem. 2008; 29 (10):1693-8. doi: 10.1002/Jcc.20933 PMID: ISI:000257038200018.
26. Zhang L, Hermans J. Hydrophilicity of cavities in proteins. Proteins-Structure Function and Genetics. 1996; 24(4):433-8. doi: 10.1002/(Sici)1097-0134(199604)24:4<433::Aid-Prot3>3.0.Co;2-F PMID: ISI: A1996UF55700004.
27. Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI. OPM: Orientations of proteins in membranes database. Bioinformatics. 2006; 22(5):623-5. doi: 10.1093/Bioinformatics/Btk023 PMID: ISI:000235604400018.
28. Tattrie NH, Bennett JR, Cyr R. Maximum and Minimum Values for Lecithin Classes from Various Biological Sources. Can J Biochem Cell B. 1968; 46(8):819-&. PMID: ISI:A1968B639900015.
29. Jambeck JPM, Lyubartsev AP. An Extension and Further Validation of an All-Atomistic Force Field for Biological Membranes. J Chem Theory Comput. 2012; 8(8):2938-48. doi: 10.1021/Ct300342n PMID: ISI:000307478800042.
30. Jambeck JPM, Lyubartsev AP. Derivation and Systematic Validation of a Refined All-Atom Force Field for Phosphatidylcholine Lipids. J Phys Chem B. 2012; 116(10):3164-79. doi: 10.1021/Jp212503e PMID: ISI:000301509500014.
31. Schmidt TH, Kandt C. LAMBADA and InflateGRO2: Efficient Membrane Alignment and Insertion of Membrane Proteins for Molecular Dynamics Simulations. J Chem Inf Model. 2012; 52(10):2657-69. doi: 10.1021/Ci3000453 PMID: ISI:000310043800018.
32. Van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: Fast, flexible, and free. J Comput Chem. 2005; 26(16):1701-18. doi: 10.1002/Jcc.20291 PMID: ISI:000233021400004.
33. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys. 1983; 79(2):926-35. doi: 10.1063/1.445869 PMID: ISI:A1983QZ31500046.
34. Aqvist J. Ion Water Interaction Potentials Derived from Free-Energy Perturbation Simulations. J Phys Chem-Us. 1990; 94(21):8021-4. PMID: ISI:A1990EE48600009.
35. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins. 2010; 78(8):1950-8. doi: 10.1002/ Prot.22711 PMID: ISI:000277767700012.
36. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian 09, Revision A.02. Wallingford CT2009.
37. Wang JM, Cieplak P, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J Comput Chem. 2000; 21(12):1049-74. doi: 10.1002/1096-987x(200009)21:12<1049::Aid-Jcc3>3.0.Co;2-F PMID: ISI:000088366200003.
38. Wang JM, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004; 25(9):1157-74. doi: 10.1002/Jcc.20035 PMID: ISI:000221624200007.
39. Andersen HC. Molecular-Dynamics Simulations at Constant Pressure and-or Temperature. J Chem Phys. 1980; 72(4):2384-93. PMID: ISI:A1980JK06800026.
40. Parrinello M, Rahman A. Polymorphic Transitions in Single-Crystals-a New Molecular-Dynamics Method. J Appl Phys. 1981; 52(12):7182-90. PMID: ISI:A1981MT07800024.
41. Nose S, Klein ML. Constant Pressure Molecular-Dynamics for Molecular-Systems. Mol Phys. 1983; 50 (5):1055-76. doi: 10.1080/00268978300102851 PMID: ISI:A1983RW97600012.
42. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. LINCS: A linear constraint solver for molecular simulations. J Comput Chem. 1997; 18(12):1463-72. doi: 10.1002/(Sici)1096-987x(199709)18:12<1463:: Aid-Jcc4>3.0.Co;2-H PMID: ISI:A1997XT81100004.
43. Darden T, Perera L, Li LP, Pedersen L. New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Struct Fold Des. 1999; 7(3):R55- R60. doi: 10.1016/S0969-2126(99)80033-1 PMID: ISI:000079411100003.
44. Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008; 4(3):435-47. doi: 10.1021/ Ct700301q PMID: ISI:000254277900007.
45. Daura X, Gademann K, Jaun B, Seebach D, van Gunsteren WF, Mark AE. Peptide folding: When simulation meets experiment. Angew Chem Int Edit. 1999; 38(1-2):236-40. 10.1002/(Sici)1521-3773 (19990115)38:1/2<236::Aid-Anie236>3.0.Co;2-M. PMID: ISI:000078230400061.
46. Kirkwood JG. Statistical mechanics of fluid mixtures. J Chem Phys. 1935; 3(5):300-13. doi: 10.1063/1. 1749657 PMID: ISI:000201218900011.
47. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical pharmacology. 1973; 22(23):3099-108. Epub 1973/12/01. PMID: 4202581.
48. Surratt CK, Johnson PS, Moriwaki A, Seidleck BK, Blaschak CJ, Wang JB, et al.-Mu Opiate Receptor -Charged Transmembrane Domain Amino-Acids Are Critical for Agonist Recognition and Intrinsic Activity. Journal of Biological Chemistry. 1994; 269(32):20548-53. PMID: ISI:A1994PB31700054.
49. Serohijos AWR, Yin SY, Ding F, Gauthier J, Gibson DG, Maixner W, et al. Structural Basis for mu-Opioid Receptor Binding and Activation. Structure. 2011; 19(11):1683-90. doi: 10.1016/J.Str.2011.08.003 PMID: ISI:000296999700019.
50. Mansour A, Taylor LP, Fine JL, Thompson RC, Hoversten MT, Mosberg HI, et al. Key residues defining the mu-opioid receptor binding pocket: A site-directed mutagenesis study. J Neurochem. 1997; 68 (1):344-53. PMID: ISI:A1997VY89300043.
51. Lau AY, Roux B. The hidden energetics of ligand binding and activation in a glutamate receptor. Nat Struct Mol Biol. 2011; 18(3):283-U62. doi: 10.1038/Nsmb.2010 PMID: ISI:000288072200007.
52. Lau AY, Roux B. The free energy landscapes governing conformational changes in a glutamate receptor ligand-binding domain. Structure. 2007; 15(10):1203-14. doi: 10.1016/J.Str.2007.07.015 PMID: ISI:000250235900008.
53. Huang P, Li J, Chen CG, Visiers I, Weinstein H, Liu-Chen LY. Functional role of a conserved motif in TM6 of the rat mu opioid receptor: Constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry-Us. 2001; 40(45):13501-9. doi: 10.1021/Bi010917q PMID: ISI:000172244400012.
54. Suwa M, Sugihara M, Ono Y. Functional and Structural Overview of G-Protein-Coupled Receptors Comprehensively Obtained from Genome Sequences. Pharmaceuticals. 2011; 4(4):652-64. doi: 10. 3390/ph4040652 PMID: PMC4055883.
55. Hofmann KP, Scheerer P, Hildebrand PW, Choe HW, Park JH, Heck M, et al. A G protein-coupled receptor at work: the rhodopsin model. Trends in biochemical sciences. 2009; 34(11):540-52. doi: 10. 1016/J.Tibs.2009.07.005 PMID: ISI:000272051300002.
56. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE. Molecular mechanism of 7TM receptor activation-A global toggle switch model. Annual Review of Pharmacology and Toxicology. 2006; 46:481-519. doi: 10.1146/Annurev.Pharmtox.46.120604.141218 PMID: ISI:000235981300017.
57. Tehan BG, Bortolato A, Blaney FE, Weir MP, Mason JS. Unifying Family A GPCR Theories of Activation. Pharmacol Therapeut. 2014; 143(1):51-60. doi: 10.1016/J.Pharmthera.2014.02.004 PMID: ISI:000335622800005.
58. Yuan SG, Vogel H, Filipek S. The Role of Water and Sodium Ions in the Activation of the mu-Opioid Receptor. Angew Chem Int Edit. 2013; 52(38):10112-5. doi: 10.1002/Anie.201302244 PMID: ISI:000324309900052.